CO-1686 (Rociletinib, AVL-301)
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Discription | CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). | ||
---|---|---|---|
Targets |
|
Catalog Num | A13028 |
---|---|
Formula | C27H28F3N7O3 |
Molecular Weight | 555.55 |
CAS Number | 1374640-70-6 |
SMILES | CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC |
Synonyms | CO1686; AVL-301; CNX-419 ;AVL 301; AVL301; CNX419 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro (25°C) | DMSO | 91 mg/mL (163.8 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80 | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18 mL | 90 mL | 180 mL |
0.5 mM | 3.6 mL | 18 mL | 36 mL |
1 mM | 1.8 mL | 9 mL | 18 mL |
5 mM | 0.36 mL | 1.8 mL | 3.6 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2